The Epidemiology of Lung Metastases
Introduction: Lung metastasis is usually associated with poor outcomes in cancer patients. This study was performed to characterize and analyze the population of patients with de novo (synchronous) lung metastases using the Surveillance, Epidemiology and End Results (SEER) database. Materials and Me...
Saved in:
Published in | Frontiers in medicine Vol. 8; p. 723396 |
---|---|
Main Authors | , , , , , , , , , |
Format | Journal Article |
Language | English |
Published |
Frontiers Media S.A
20.09.2021
|
Subjects | |
Online Access | Get full text |
Cover
Loading…
Abstract | Introduction:
Lung metastasis is usually associated with poor outcomes in cancer patients. This study was performed to characterize and analyze the population of patients with
de novo
(synchronous) lung metastases using the Surveillance, Epidemiology and End Results (SEER) database.
Materials and Methods:
Baseline characteristics of lung metastasis patients were obtained from SEER case listings. Incidence rates and counts of synchronous lung metastasis were also obtained using the SEER
*
Stat software. Survival outcomes were analyzed using univariate and multivariable Cox regressions, controlling for confounders. An alpha threshold of 0.05 was used for statistical significance and
p
-values were subject to correction for multiple comparisons.
Results:
The age-adjusted incidence rate of synchronous lung metastasis was 17.92 per 100,000 between 2010 and 2015. Synchronous lung metastases most commonly arose from primary lung cancers, colorectal cancers, kidney cancers, pancreatic cancers and breast cancers. During this time period, 4% of all cancer cases presented with synchronous lung metastasis. The percentage of patients presenting with synchronous lung metastasis ranged from 0.5% of all prostate cancers to 13% of all primary lung cancers. The percentage of all cancer cases presenting with synchronous lung metastasis increased over time.
De novo
metastatic patients with lung metastases had worse overall survival [hazard ratio = 1.22 (1.21–1.23),
p
< 0.001] compared to those with only extrapulmonary metastases, controlling for potential confounders.
Conclusions:
Synchronous lung metastasis occurs frequently and is an independent predictors of poor patient outcomes. As treatment for lung metastases becomes more complicated, patients with synchronous lung metastasis represent a high-risk population. |
---|---|
AbstractList | Introduction:
Lung metastasis is usually associated with poor outcomes in cancer patients. This study was performed to characterize and analyze the population of patients with
de novo
(synchronous) lung metastases using the Surveillance, Epidemiology and End Results (SEER) database.
Materials and Methods:
Baseline characteristics of lung metastasis patients were obtained from SEER case listings. Incidence rates and counts of synchronous lung metastasis were also obtained using the SEER
*
Stat software. Survival outcomes were analyzed using univariate and multivariable Cox regressions, controlling for confounders. An alpha threshold of 0.05 was used for statistical significance and
p
-values were subject to correction for multiple comparisons.
Results:
The age-adjusted incidence rate of synchronous lung metastasis was 17.92 per 100,000 between 2010 and 2015. Synchronous lung metastases most commonly arose from primary lung cancers, colorectal cancers, kidney cancers, pancreatic cancers and breast cancers. During this time period, 4% of all cancer cases presented with synchronous lung metastasis. The percentage of patients presenting with synchronous lung metastasis ranged from 0.5% of all prostate cancers to 13% of all primary lung cancers. The percentage of all cancer cases presenting with synchronous lung metastasis increased over time.
De novo
metastatic patients with lung metastases had worse overall survival [hazard ratio = 1.22 (1.21–1.23),
p
< 0.001] compared to those with only extrapulmonary metastases, controlling for potential confounders.
Conclusions:
Synchronous lung metastasis occurs frequently and is an independent predictors of poor patient outcomes. As treatment for lung metastases becomes more complicated, patients with synchronous lung metastasis represent a high-risk population. Introduction: Lung metastasis is usually associated with poor outcomes in cancer patients. This study was performed to characterize and analyze the population of patients with de novo (synchronous) lung metastases using the Surveillance, Epidemiology and End Results (SEER) database.Materials and Methods: Baseline characteristics of lung metastasis patients were obtained from SEER case listings. Incidence rates and counts of synchronous lung metastasis were also obtained using the SEER*Stat software. Survival outcomes were analyzed using univariate and multivariable Cox regressions, controlling for confounders. An alpha threshold of 0.05 was used for statistical significance and p-values were subject to correction for multiple comparisons.Results: The age-adjusted incidence rate of synchronous lung metastasis was 17.92 per 100,000 between 2010 and 2015. Synchronous lung metastases most commonly arose from primary lung cancers, colorectal cancers, kidney cancers, pancreatic cancers and breast cancers. During this time period, 4% of all cancer cases presented with synchronous lung metastasis. The percentage of patients presenting with synchronous lung metastasis ranged from 0.5% of all prostate cancers to 13% of all primary lung cancers. The percentage of all cancer cases presenting with synchronous lung metastasis increased over time. De novo metastatic patients with lung metastases had worse overall survival [hazard ratio = 1.22 (1.21–1.23), p < 0.001] compared to those with only extrapulmonary metastases, controlling for potential confounders.Conclusions: Synchronous lung metastasis occurs frequently and is an independent predictors of poor patient outcomes. As treatment for lung metastases becomes more complicated, patients with synchronous lung metastasis represent a high-risk population. Introduction: Lung metastasis is usually associated with poor outcomes in cancer patients. This study was performed to characterize and analyze the population of patients with de novo (synchronous) lung metastases using the Surveillance, Epidemiology and End Results (SEER) database. Materials and Methods: Baseline characteristics of lung metastasis patients were obtained from SEER case listings. Incidence rates and counts of synchronous lung metastasis were also obtained using the SEER*Stat software. Survival outcomes were analyzed using univariate and multivariable Cox regressions, controlling for confounders. An alpha threshold of 0.05 was used for statistical significance and p-values were subject to correction for multiple comparisons. Results: The age-adjusted incidence rate of synchronous lung metastasis was 17.92 per 100,000 between 2010 and 2015. Synchronous lung metastases most commonly arose from primary lung cancers, colorectal cancers, kidney cancers, pancreatic cancers and breast cancers. During this time period, 4% of all cancer cases presented with synchronous lung metastasis. The percentage of patients presenting with synchronous lung metastasis ranged from 0.5% of all prostate cancers to 13% of all primary lung cancers. The percentage of all cancer cases presenting with synchronous lung metastasis increased over time. De novo metastatic patients with lung metastases had worse overall survival [hazard ratio = 1.22 (1.21-1.23), p < 0.001] compared to those with only extrapulmonary metastases, controlling for potential confounders. Conclusions: Synchronous lung metastasis occurs frequently and is an independent predictors of poor patient outcomes. As treatment for lung metastases becomes more complicated, patients with synchronous lung metastasis represent a high-risk population.Introduction: Lung metastasis is usually associated with poor outcomes in cancer patients. This study was performed to characterize and analyze the population of patients with de novo (synchronous) lung metastases using the Surveillance, Epidemiology and End Results (SEER) database. Materials and Methods: Baseline characteristics of lung metastasis patients were obtained from SEER case listings. Incidence rates and counts of synchronous lung metastasis were also obtained using the SEER*Stat software. Survival outcomes were analyzed using univariate and multivariable Cox regressions, controlling for confounders. An alpha threshold of 0.05 was used for statistical significance and p-values were subject to correction for multiple comparisons. Results: The age-adjusted incidence rate of synchronous lung metastasis was 17.92 per 100,000 between 2010 and 2015. Synchronous lung metastases most commonly arose from primary lung cancers, colorectal cancers, kidney cancers, pancreatic cancers and breast cancers. During this time period, 4% of all cancer cases presented with synchronous lung metastasis. The percentage of patients presenting with synchronous lung metastasis ranged from 0.5% of all prostate cancers to 13% of all primary lung cancers. The percentage of all cancer cases presenting with synchronous lung metastasis increased over time. De novo metastatic patients with lung metastases had worse overall survival [hazard ratio = 1.22 (1.21-1.23), p < 0.001] compared to those with only extrapulmonary metastases, controlling for potential confounders. Conclusions: Synchronous lung metastasis occurs frequently and is an independent predictors of poor patient outcomes. As treatment for lung metastases becomes more complicated, patients with synchronous lung metastasis represent a high-risk population. |
Author | Meng, Mao-Bin Stoltzfus, Kelsey C. Trifiletti, Daniel M. Horn, Samantha R. Verma, Vivek Chen, Hanbo Siva, Shankar Zaorsky, Nicholas G. Lehrer, Eric J. Louie, Alexander V. |
AuthorAffiliation | 9 Department of Radiation Oncology, Sunnybrook Health Sciences Centre , Toronto, ON , Canada 3 Department of Public Health Sciences, Penn State Health Milton S. Hershey Medical Center , Hershey, PA , United States 5 Department of Radiation Oncology, Peter MacCallum Cancer Centre , Melbourne, VIC , Australia 6 Department of Radiation Oncology, Mayo Clinic , Jacksonville, FL , United States 4 Department of Radiation Oncology, Icahn School of Medicine at Mount Sinai , New York, NY , United States 7 Department of Radiation Oncology, Tianjin Medical University Cancer Institute and Hospital , Tianjin , China 8 Department of Radiation Oncology, Allegheny General Hospital , Pittsburgh, PA , United States 1 Department of Radiation Oncology, Amsterdam University Medical Centers , Amsterdam , Netherlands 2 Department of Radiation Oncology, Penn State Cancer Institute , Hershey, PA , United States |
AuthorAffiliation_xml | – name: 5 Department of Radiation Oncology, Peter MacCallum Cancer Centre , Melbourne, VIC , Australia – name: 2 Department of Radiation Oncology, Penn State Cancer Institute , Hershey, PA , United States – name: 1 Department of Radiation Oncology, Amsterdam University Medical Centers , Amsterdam , Netherlands – name: 6 Department of Radiation Oncology, Mayo Clinic , Jacksonville, FL , United States – name: 7 Department of Radiation Oncology, Tianjin Medical University Cancer Institute and Hospital , Tianjin , China – name: 4 Department of Radiation Oncology, Icahn School of Medicine at Mount Sinai , New York, NY , United States – name: 8 Department of Radiation Oncology, Allegheny General Hospital , Pittsburgh, PA , United States – name: 9 Department of Radiation Oncology, Sunnybrook Health Sciences Centre , Toronto, ON , Canada – name: 3 Department of Public Health Sciences, Penn State Health Milton S. Hershey Medical Center , Hershey, PA , United States |
Author_xml | – sequence: 1 givenname: Hanbo surname: Chen fullname: Chen, Hanbo – sequence: 2 givenname: Kelsey C. surname: Stoltzfus fullname: Stoltzfus, Kelsey C. – sequence: 3 givenname: Eric J. surname: Lehrer fullname: Lehrer, Eric J. – sequence: 4 givenname: Samantha R. surname: Horn fullname: Horn, Samantha R. – sequence: 5 givenname: Shankar surname: Siva fullname: Siva, Shankar – sequence: 6 givenname: Daniel M. surname: Trifiletti fullname: Trifiletti, Daniel M. – sequence: 7 givenname: Mao-Bin surname: Meng fullname: Meng, Mao-Bin – sequence: 8 givenname: Vivek surname: Verma fullname: Verma, Vivek – sequence: 9 givenname: Alexander V. surname: Louie fullname: Louie, Alexander V. – sequence: 10 givenname: Nicholas G. surname: Zaorsky fullname: Zaorsky, Nicholas G. |
BookMark | eNp1kU1rGzEQhkVISBw39xwNvfRidzT6WO2lUEy-wCGXBHITknbWkVmvnNW6kH_f3TiFplAYmEEz76Nh3nN23KaWGLvksBDClN_rLVULBOSLAoUo9RGbIJZ6bpR5Pv6rPmMXOW8AgAtUkotTdiak5rpQcsK-Pr7Q7GoXK9rG1KT12yzVs9W-Xc_uqXd5CMpf2EntmkwXH3nKnq6vHpe389XDzd3y52oeFKh-rkxFiOADoCA0dVlrkmA8Oi0DylIRL6QcprBwQQJWXohCQSDkqvayFlN2d-BWyW3srotb173Z5KJ9f0jd2rquj6EhC9JjkN4pEbQUHkrPteYDWxgdfFkOrB8H1m7vhzsFavvONZ-gnzttfLHr9MsaaQwHPQC-fQC69Lqn3NttzIGaxrWU9tmiMgCoeTH-pQ-joUs5d1TbEHvXxzSSY2M52NEwOxpmR8PswbBBCP8I_-z3X8lvTUiX4g |
CitedBy_id | crossref_primary_10_1136_bmjopen_2023_072469 crossref_primary_10_1007_s11864_023_01144_6 crossref_primary_10_3390_diagnostics12092254 crossref_primary_10_1111_cas_15951 crossref_primary_10_20517_evcna_2023_77 crossref_primary_10_1210_jendso_bvaf034 crossref_primary_10_3390_cancers16112080 crossref_primary_10_3390_cancers17020206 crossref_primary_10_3389_fcell_2024_1449232 crossref_primary_10_3390_diagnostics13010165 crossref_primary_10_1515_oncologie_2024_0138 crossref_primary_10_1007_s11604_022_01302_0 crossref_primary_10_12998_wjcc_v10_i30_10882 crossref_primary_10_1089_thy_2023_0709 crossref_primary_10_1002_rcr2_70031 crossref_primary_10_3389_fcvm_2022_1009765 crossref_primary_10_1021_acsnano_3c03980 crossref_primary_10_3390_cancers16193365 crossref_primary_10_1007_s00281_022_00964_2 crossref_primary_10_1038_s41392_025_02148_4 crossref_primary_10_1007_s10555_023_10120_3 crossref_primary_10_1007_s41973_024_00263_3 crossref_primary_10_1615_CritRevImmunol_2024051316 crossref_primary_10_1038_s43856_023_00304_x crossref_primary_10_3389_fonc_2023_1116783 crossref_primary_10_1002_advs_202308237 |
Cites_doi | 10.1016/j.radonc.2011.05.033 10.1001/archsurg.142.1.70 10.1016/S0140-6736(18)32487-5 10.1002/cam4.1697 10.3747/co.25.4103 10.1093/annonc/mdq220 10.1136/gut.2010.211557 10.1002/cncr.21778 10.1002/cncr.31549 10.1093/annonc/mdw235 10.1378/chest.12-2346 10.1007/s10585-015-9719-0 10.1016/j.clcc.2017.12.005 10.1126/science.1150224 10.1016/j.cllc.2014.07.001 10.1080/08998280.2005.11928089 10.1093/annonc/mdv037 10.1016/j.eururo.2012.05.068 10.1186/1471-2407-13-36 10.1177/1010428317705082 10.1016/S0003-4975(00)02522-4 10.1038/srep29765 10.1093/jnci/djq029 10.1016/j.lungcan.2014.07.020 10.18632/oncotarget.10740 10.1097/00000658-199905000-00002 10.1016/S0895-4356(00)00314-0 10.1007/s10585-016-9824-8 10.1038/nature03799 10.1111/j.1365-2605.1987.tb00188.x 10.1016/j.cllc.2014.04.003 |
ContentType | Journal Article |
Copyright | Copyright © 2021 Chen, Stoltzfus, Lehrer, Horn, Siva, Trifiletti, Meng, Verma, Louie and Zaorsky. Copyright © 2021 Chen, Stoltzfus, Lehrer, Horn, Siva, Trifiletti, Meng, Verma, Louie and Zaorsky. 2021 Chen, Stoltzfus, Lehrer, Horn, Siva, Trifiletti, Meng, Verma, Louie and Zaorsky |
Copyright_xml | – notice: Copyright © 2021 Chen, Stoltzfus, Lehrer, Horn, Siva, Trifiletti, Meng, Verma, Louie and Zaorsky. – notice: Copyright © 2021 Chen, Stoltzfus, Lehrer, Horn, Siva, Trifiletti, Meng, Verma, Louie and Zaorsky. 2021 Chen, Stoltzfus, Lehrer, Horn, Siva, Trifiletti, Meng, Verma, Louie and Zaorsky |
DBID | AAYXX CITATION 7X8 5PM DOA |
DOI | 10.3389/fmed.2021.723396 |
DatabaseName | CrossRef MEDLINE - Academic PubMed Central (Full Participant titles) DOAJ Directory of Open Access Journals |
DatabaseTitle | CrossRef MEDLINE - Academic |
DatabaseTitleList | CrossRef MEDLINE - Academic |
Database_xml | – sequence: 1 dbid: DOA name: DOAJ Directory of Open Access Journals url: https://www.doaj.org/ sourceTypes: Open Website |
DeliveryMethod | fulltext_linktorsrc |
Discipline | Medicine |
EISSN | 2296-858X |
ExternalDocumentID | oai_doaj_org_article_04b2c4ba53c643b09b166158d386cb99 PMC8488106 10_3389_fmed_2021_723396 |
GroupedDBID | 53G 5VS 9T4 AAFWJ AAYXX ACGFS ACXDI ADBBV ADRAZ AFPKN ALMA_UNASSIGNED_HOLDINGS AOIJS BAWUL BCNDV CITATION DIK GROUPED_DOAJ HYE KQ8 M48 M~E OK1 PGMZT RPM 7X8 5PM |
ID | FETCH-LOGICAL-c505t-58de220bc023e28f9f6e408b2a64c2495e174458d27ac402db33750ce215fb4f3 |
IEDL.DBID | DOA |
ISSN | 2296-858X |
IngestDate | Wed Aug 27 01:21:10 EDT 2025 Thu Aug 21 18:16:44 EDT 2025 Fri Jul 11 05:23:29 EDT 2025 Tue Jul 01 03:03:23 EDT 2025 Thu Apr 24 22:56:51 EDT 2025 |
IsDoiOpenAccess | true |
IsOpenAccess | true |
IsPeerReviewed | true |
IsScholarly | true |
Language | English |
License | This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms. |
LinkModel | DirectLink |
MergedId | FETCHMERGED-LOGICAL-c505t-58de220bc023e28f9f6e408b2a64c2495e174458d27ac402db33750ce215fb4f3 |
Notes | ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 content type line 23 Edited by: Michel Gonzalez, Centre Hospitalier Universitaire Vaudois (CHUV), Switzerland Reviewed by: Manigreeva Krishnatreya, Bhubaneswar Borooah Cancer Institute, India; Levent Cansever, Yedikule Teaching Hospital, Turkey This article was submitted to Pulmonary Medicine, a section of the journal Frontiers in Medicine |
OpenAccessLink | https://doaj.org/article/04b2c4ba53c643b09b166158d386cb99 |
PMID | 34616754 |
PQID | 2580026179 |
PQPubID | 23479 |
ParticipantIDs | doaj_primary_oai_doaj_org_article_04b2c4ba53c643b09b166158d386cb99 pubmedcentral_primary_oai_pubmedcentral_nih_gov_8488106 proquest_miscellaneous_2580026179 crossref_citationtrail_10_3389_fmed_2021_723396 crossref_primary_10_3389_fmed_2021_723396 |
ProviderPackageCode | CITATION AAYXX |
PublicationCentury | 2000 |
PublicationDate | 2021-09-20 |
PublicationDateYYYYMMDD | 2021-09-20 |
PublicationDate_xml | – month: 09 year: 2021 text: 2021-09-20 day: 20 |
PublicationDecade | 2020 |
PublicationTitle | Frontiers in medicine |
PublicationYear | 2021 |
Publisher | Frontiers Media S.A |
Publisher_xml | – name: Frontiers Media S.A |
References | Billingsley (B7) 1999; 229 Wang (B22) 2018; 17 Ording (B20) 2017; 34 B26 B27 B28 Bender (B30) 2001; 54 Riihimaki (B4) 2016; 6 Pagani (B10) 2010; 102 Loukeri (B36) 2015; 16 van der Geest (B21) 2015; 32 Palma (B8) 2019; 393 Negoita (B33) 2018; 124 Mitry (B2) 2010; 59 Ashworth (B23) 2014; 15 Riihimaki (B5) 2016; 7 B34 Gao (B12) 2008; 319 Schroder (B32) 2012; 62 B37 Minn (B11) 2005; 436 Hess (B18) 2006; 106 Vogelzang (B1) 1987; 10 Rehders (B13) 2007; 142 Headrick (B14) 2001; 71 Holm (B29) 1979; 6 Van Cutsem (B9) 2016; 27 Wu SG Li (B19) 2017; 39 Dawood (B25) 2010; 21 Nana-Sinkam (B35) 2013; 143 Takeda (B16) 2011; 101 Nazha (B24) 2018; 25 Riihimaki (B6) 2013; 13 Riihimaki (B17) 2018; 7 Griffeth (B31) 2005; 18 Riihimaki (B3) 2014; 86 de Baere (B15) 2015; 26 |
References_xml | – volume: 101 start-page: 255 year: 2011 ident: B16 article-title: Stereotactic body radiotherapy (SBRT) for oligometastatic lung tumors from colorectal cancer and other primary cancers in comparison with primary lung cancer publication-title: Radiother Oncol. doi: 10.1016/j.radonc.2011.05.033 – volume: 142 start-page: 70 year: 2007 ident: B13 article-title: Benefit of surgical treatment of lung metastasis in soft tissue sarcoma publication-title: Arch Surg. doi: 10.1001/archsurg.142.1.70 – volume: 6 start-page: 65 year: 1979 ident: B29 article-title: A simple sequentially rejective multiple test procedure publication-title: Scand J Statist. – volume: 393 start-page: 2051 year: 2019 ident: B8 article-title: Stereotactic ablative radiotherapy versus standard of care palliative treatment in patients with oligometastatic cancers (SABR-COMET): a randomised, phase 2, open-label trial publication-title: Lancet. doi: 10.1016/S0140-6736(18)32487-5 – volume: 7 start-page: 5534 year: 2018 ident: B17 article-title: Clinical landscape of cancer metastases publication-title: Cancer Med. doi: 10.1002/cam4.1697 – volume: 25 start-page: e576 year: 2018 ident: B24 article-title: Use of targeted therapy in patients with metastatic renal cell carcinoma: clinical and economic impact in a Canadian real-life setting publication-title: Curr Oncol. doi: 10.3747/co.25.4103 – ident: B27 – volume: 21 start-page: 2169 year: 2010 ident: B25 article-title: Survival differences among women with de novo stage IV and relapsed breast cancer publication-title: Ann Oncol. doi: 10.1093/annonc/mdq220 – volume: 59 start-page: 1383 year: 2010 ident: B2 article-title: Epidemiology, management and prognosis of colorectal cancer with lung metastases: a 30-year population-based study publication-title: Gut. doi: 10.1136/gut.2010.211557 – volume: 106 start-page: 1624 year: 2006 ident: B18 article-title: Metastatic patterns in adenocarcinoma publication-title: Cancer. doi: 10.1002/cncr.21778 – volume: 124 start-page: 2801 year: 2018 ident: B33 article-title: Annual Report to the Nation on the Status of Cancer, part II: recent changes in prostate cancer trends and disease characteristics publication-title: Cancer. doi: 10.1002/cncr.31549 – volume: 27 start-page: 1386 year: 2016 ident: B9 article-title: ESMO consensus guidelines for the management of patients with metastatic colorectal cancer publication-title: Ann Oncol. doi: 10.1093/annonc/mdw235 – volume: 143 start-page: e30S year: 2013 ident: B35 article-title: Molecular biology of lung cancer: diagnosis and management of lung cancer, 3rd ed: American College of Chest Physicians evidence-based clinical practice guidelines publication-title: Chest doi: 10.1378/chest.12-2346 – volume: 32 start-page: 457 year: 2015 ident: B21 article-title: Nationwide trends in incidence, treatment and survival of colorectal cancer patients with synchronous metastases publication-title: Clin Exp Metastasis. doi: 10.1007/s10585-015-9719-0 – volume: 17 start-page: e233 year: 2018 ident: B22 article-title: Survival benefit of palliative local treatments and efficacy of different pharmacotherapies in colorectal cancer with lung metastasis: results from a large retrospective study publication-title: Clin Colorectal Cancer. doi: 10.1016/j.clcc.2017.12.005 – volume: 319 start-page: 195 year: 2008 ident: B12 article-title: Endothelial progenitor cells control the angiogenic switch in mouse lung metastasis publication-title: Science. doi: 10.1126/science.1150224 – volume: 16 start-page: 15 year: 2015 ident: B36 article-title: Metachronous and synchronous primary lung cancers: diagnostic aspects, surgical treatment, and prognosis publication-title: Clin Lung Cancer. doi: 10.1016/j.cllc.2014.07.001 – volume: 18 start-page: 321 year: 2005 ident: B31 article-title: Use of PET/CT scanning in cancer patients: technical and practical considerations publication-title: Proc. doi: 10.1080/08998280.2005.11928089 – ident: B37 – volume: 26 start-page: 987 year: 2015 ident: B15 article-title: Radiofrequency ablation is a valid treatment option for lung metastases: experience in 566 patients with 1037 metastases publication-title: Ann Oncol. doi: 10.1093/annonc/mdv037 – volume: 62 start-page: 745 year: 2012 ident: B32 article-title: Screening for prostate cancer decreases the risk of developing metastatic disease: findings from the European Randomized Study of Screening for Prostate Cancer (ERSPC) publication-title: Eur Urol. doi: 10.1016/j.eururo.2012.05.068 – volume: 13 start-page: 36 year: 2013 ident: B6 article-title: Comparison of survival of patients with metastases from known versus unknown primaries: survival in metastatic cancer publication-title: BMC Cancer. doi: 10.1186/1471-2407-13-36 – volume: 39 start-page: 1010428317705082 year: 2017 ident: B19 article-title: The effect of distant metastases sites on survival in de novo stage-IV breast cancer: a SEER database analysis publication-title: Tumour Biol. doi: 10.1177/1010428317705082 – volume: 71 start-page: 975 year: 2001 ident: B14 article-title: Surgical treatment of hepatic and pulmonary metastases from colon cancer publication-title: Ann Thorac Surg. doi: 10.1016/S0003-4975(00)02522-4 – volume: 6 start-page: 29765 year: 2016 ident: B4 article-title: Patterns of metastasis in colon and rectal cancer publication-title: Sci Rep. doi: 10.1038/srep29765 – ident: B26 – volume: 102 start-page: 456 year: 2010 ident: B10 article-title: International guidelines for management of metastatic breast cancer: can metastatic breast cancer be cured? publication-title: J Natl Cancer Inst. doi: 10.1093/jnci/djq029 – ident: B28 – volume: 86 start-page: 78 year: 2014 ident: B3 article-title: Metastatic sites and survival in lung cancer publication-title: Lung Cancer. doi: 10.1016/j.lungcan.2014.07.020 – volume: 7 start-page: 52307 year: 2016 ident: B5 article-title: Metastatic spread in patients with gastric cancer publication-title: Oncotarget. doi: 10.18632/oncotarget.10740 – volume: 229 start-page: 602 year: 1999 ident: B7 article-title: Pulmonary metastases from soft tissue sarcoma: analysis of patterns of diseases and postmetastasis survival publication-title: Ann Surg. doi: 10.1097/00000658-199905000-00002 – volume: 54 start-page: 343 year: 2001 ident: B30 article-title: Adjusting for multiple testing–when and how? publication-title: J Clin Epidemiol. doi: 10.1016/S0895-4356(00)00314-0 – volume: 34 start-page: 93 year: 2017 ident: B20 article-title: Site of metastasis and breast cancer mortality: a Danish nationwide registry-based cohort study publication-title: Clin Exp Metastasis. doi: 10.1007/s10585-016-9824-8 – volume: 436 start-page: 518 year: 2005 ident: B11 article-title: Genes that mediate breast cancer metastasis to lung publication-title: Nature. doi: 10.1038/nature03799 – volume: 10 start-page: 225 year: 1987 ident: B1 article-title: Prognostic factors in metastatic testicular cancer publication-title: Int J Androl. doi: 10.1111/j.1365-2605.1987.tb00188.x – volume: 15 start-page: 346 year: 2014 ident: B23 article-title: An individual patient data metaanalysis of outcomes and prognostic factors after treatment of oligometastatic non-small-cell lung cancer publication-title: Clin Lung Cancer. doi: 10.1016/j.cllc.2014.04.003 – ident: B34 |
SSID | ssj0001325413 |
Score | 2.361005 |
Snippet | Introduction:
Lung metastasis is usually associated with poor outcomes in cancer patients. This study was performed to characterize and analyze the population... Introduction: Lung metastasis is usually associated with poor outcomes in cancer patients. This study was performed to characterize and analyze the population... |
SourceID | doaj pubmedcentral proquest crossref |
SourceType | Open Website Open Access Repository Aggregation Database Enrichment Source Index Database |
StartPage | 723396 |
SubjectTerms | cancer epidemiology lung cancer Medicine metastases oncology |
SummonAdditionalLinks | – databaseName: Scholars Portal Journals: Open Access dbid: M48 link: http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwrV1LS8NAEF60gngRn1hfRPTiITXd3bwOIiotRYwnC70tu5uNCiXRJgX7751J0tZA8eQlh2Q3j5lM5vt2N98QciVRZQ0H3WM_BoISutqWNJGwCY30Eyd0NP47HL14gyF_Grmj5e_RtQHzldQO60kNJ-PO99fsDgL-Fhkn5FvwgEHNT9rt-JSx0FsnG5CXfAzTqAb75YgLAzLUZdVc5cqOjdxUSvg3cGdz1eSvNNTfIds1frTuK4fvkjWT7pHNqJ4h3yeX4Hertyz7OrOyxHqGiLYiU0iAgrnJD8iw33t9HNh1IQRbA0ApbDeIDaWO0pBgDQ2SMPEMdwJFpcc1Fo82wCs4tKK-1EAIY8UYIAFtIJ8niifskLTSLDVHxGLdOOFeAEQh5twPZHkOlA8HnMeYx9rkZm4CoWuVcCxWMRbAFtBoAo0m0GiiMlqbXC96fFYKGX-0fUCrLtqhtnW5I5u8iTpUhMMV1VxJl2mAS8oJVRdABDwdCzytwrBNLuY-ERALOMEhU5NNc0HdoJKYhzZ-w1mNKzaPpB_vpap2AJ8y4MfH_3GLJ2QLnxrXlVDnlLSKydScAXgp1Hn5Tv4AzLTrPg priority: 102 providerName: Scholars Portal |
Title | The Epidemiology of Lung Metastases |
URI | https://www.proquest.com/docview/2580026179 https://pubmed.ncbi.nlm.nih.gov/PMC8488106 https://doaj.org/article/04b2c4ba53c643b09b166158d386cb99 |
Volume | 8 |
hasFullText | 1 |
inHoldings | 1 |
isFullTextHit | |
isPrint | |
link | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwrV07T8MwELYQA2JBPEV5KQgWhtDEdhJnBNSqQoSJSt0s27EFEkoRTQf-PXdxWpIFFpYMiZPYd06--_z4jpBrhSprOOheZiUQlDwxoaJOwSG3KnNRHhncO1w8p5Mpf5wls06qL1wT5uWBveGGEdfUcK0SZgA8dZTrGCAlESUTqdF5s3UPMK9DpprRFQbEJ2Z-XhJYWA5usigMSuPbjDKGGv0dHGrk-nsxZn-FZAdyxrtkp40Vgztfxz2yYat9slW0s-EH5Ap8HIx-Urx-BXMXPMHXGxS2VhD2LezikEzHo5eHSdgmPQgNBCN1CC2zlEbaAJhaKlzuUssjoalKucFE0RY4BIdSNFMGyF-pGQPUNxaw22nu2BHZrOaVPSYBi0vHUwGkoOQ8E6p5BkqFQ0zHWMoGZLgygTStIjgmpniXwAzQaBKNJtFo0httQG7Wd3x4NYxfyt6jVdflUMe6OQHela135V_eHZDLlU8k9HuczFCVnS8XkibCy8lDmaznrN4b-1eqt9dGQVvAbwu48Ml_VPGUbGOrcQ0Jjc7IZv25tOcQqNT6oumTcCy4-Ab20OPb |
linkProvider | Directory of Open Access Journals |
openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=The+Epidemiology+of+Lung+Metastases&rft.jtitle=Frontiers+in+medicine&rft.au=Hanbo+Chen&rft.au=Kelsey+C.+Stoltzfus&rft.au=Kelsey+C.+Stoltzfus&rft.au=Eric+J.+Lehrer&rft.date=2021-09-20&rft.pub=Frontiers+Media+S.A&rft.eissn=2296-858X&rft.volume=8&rft_id=info:doi/10.3389%2Ffmed.2021.723396&rft.externalDBID=DOA&rft.externalDocID=oai_doaj_org_article_04b2c4ba53c643b09b166158d386cb99 |
thumbnail_l | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=2296-858X&client=summon |
thumbnail_m | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=2296-858X&client=summon |
thumbnail_s | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=2296-858X&client=summon |